Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07754461 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

StatusRecruiting
PhasePhase 3
Started2026-08-24
View on ClinicalTrials.gov ↗

Amendment history

2026-09-02
minor
Study Status, Contacts/Locations v2
Study sites120→121
2026-08-20
notable
Study Status, Contacts/Locations v1
Recruitment opened
Trial sites expanded: 115 → 120 locations
2026-08-05
minor
Original filing
4,247 trials monitored
See 176 trials at risk
2,082 trials monitored
See 101 trials at risk
This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join. The study has 3 parts. In each part the study compares survodutide with placebo. Survodutide is being developed to treat several health problems including type 2 diabetes. Placebo looks like survodutide but does not contain any medicine. Depending on a person's diabetes treatment, a person will be assigned either to * Part A: healthy eating and physical activity * Part B: diabetes tablets (no injection of insulin) * Part C: injection of insulin (with or without diabetes tablets) Participants are randomly put into 1 of 3 groups, which means the group is chosen by chance. Two groups of participants get survodutide at different dose levels, and the third group gets placebo as injection under the skin once a week. You have a 2 in 3 chance of getting survodutide. During the study, participants continue their regular diabetes treatment. Participants are in the study for about 1 year and 2 months. During this time, they attend up to 12 visits at the site and receive at least 9 phone calls. Study doctors regularly test participants' blood sugar by checking their HbA1c values and other laboratory test results. The study doctor also regularly checks participants' health and takes note of any changes. For each study part, the results will be compared between the survodutide and the placebo group to see whether the treatment works.
Trial Details
NCT Number NCT07754461
Lead Sponsor Boehringer Ingelheim
Conditions Type 2 Diabetes
Enrollment 600 participants
Start Date 2026-08-24
Primary Completion 2028-01-17 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-30